Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials

BACKGROUND: Validation of the prognostic value of the SIOPEN mIBG skeletal scoring system in two independent stage 4, mIBG avid, high-risk neuroblastoma populations. RESULTS: The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0–6 scale in 12 anatomical...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Ladenstein, Ruth, Lambert, Bieke, Pötschger, Ulrike, Castellani, Maria-Rita, Lewington, Valerie, Bar-Sever, Zvi, Oudoux, Aurore, Śliwińska, Anna, Taborska, Katerina, Biassoni, Lorenzo, Yanik, Gregory A., Naranjo, Arlene, Parisi, Marguerite T., Shulkin, Barry L., Nadel, Helen, Gelfand, Michael J., Matthay, Katherine K., Park, Julie R., Kreissman, Susan G., Valteau-Couanet, Dominique, Boubaker, Ariane
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747549/
https://ncbi.nlm.nih.gov/pubmed/28940046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3829-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars